Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1889 1
1891 1
1948 1
1949 2
1951 3
1952 1
1953 3
1955 4
1959 1
1961 2
1962 3
1963 5
1965 2
1966 2
1967 1
1969 4
1970 5
1971 6
1972 7
1973 5
1974 9
1975 2
1976 7
1977 3
1978 10
1979 9
1980 6
1981 11
1982 23
1983 15
1984 19
1985 16
1986 15
1987 22
1988 24
1989 23
1990 20
1991 26
1992 25
1993 25
1994 15
1995 21
1996 17
1997 18
1998 7
1999 18
2000 7
2001 8
2002 11
2003 6
2004 3
2005 3
2006 4
2007 7
2008 10
2009 5
2010 9
2011 10
2012 11
2013 3
2014 8
2015 13
2016 4
2017 4
2018 9
2019 7
2020 7
Text availability
Article attribute
Article type
Publication date

Search Results

603 results
Results by year
Filters applied: . Clear all
Page 1
Redirecting the revolution: new developments in drug development for psychiatry.
Brady LS, Potter WZ, Gordon JA. Brady LS, et al. Among authors: potter wz. Expert Opin Drug Discov. 2019 Dec;14(12):1213-1219. doi: 10.1080/17460441.2019.1666102. Epub 2019 Sep 23. Expert Opin Drug Discov. 2019. PMID: 31545131 No abstract available.
The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development.
Krystal AD, Pizzagalli DA, Mathew SJ, Sanacora G, Keefe R, Song A, Calabrese J, Goddard A, Goodman W, Lisanby SH, Smoski M, Weiner R, Iosifescu D, Nurnberger J Jr, Szabo S, Murrough J, Shekhar A, Potter W. Krystal AD, et al. Among authors: potter w. Nat Rev Drug Discov. 2018 Dec 28;18(1):82-84. doi: 10.1038/nrd.2018.222. Nat Rev Drug Discov. 2018. PMID: 30591715 Free PMC article. No abstract available.
Posterior quadratus lumborum block for primary total hip arthroplasty analgesia: a comparative study.
Kukreja P, MacBeth L, Potter W, Buddemeyer K, DeBell H, Elsharkawy H, Kalagara H, Wajnsztejn A, Pires EA, Godoy-Santos AL, Shah A. Kukreja P, et al. Among authors: potter w. Einstein (Sao Paulo). 2019 Sep 9;17(4):eAO4905. doi: 10.31744/einstein_journal/2019AO4905. Einstein (Sao Paulo). 2019. PMID: 31508661 Free PMC article.
Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial.
Javitt DC, Carter CS, Krystal JH, Kantrowitz JT, Girgis RR, Kegeles LS, Ragland JD, Maddock RJ, Lesh TA, Tanase C, Corlett PR, Rothman DL, Mason G, Qiu M, Robinson J, Potter WZ, Carlson M, Wall MM, Choo TH, Grinband J, Lieberman JA. Javitt DC, et al. Among authors: potter wz. JAMA Psychiatry. 2018 Jan 1;75(1):11-19. doi: 10.1001/jamapsychiatry.2017.3572. JAMA Psychiatry. 2018. PMID: 29167877 Free PMC article. Clinical Trial.
A multicenter study of ketamine effects on functional connectivity: Large scale network relationships, hubs and symptom mechanisms.
Fleming LM, Javitt DC, Carter CS, Kantrowitz JT, Girgis RR, Kegeles LS, Ragland JD, Maddock RJ, Lesh TA, Tanase C, Robinson J, Potter WZ, Carlson M, Wall MM, Choo TH, Grinband J, Lieberman J, Krystal JH, Corlett PR. Fleming LM, et al. Among authors: potter wz. Neuroimage Clin. 2019;22:101739. doi: 10.1016/j.nicl.2019.101739. Epub 2019 Feb 28. Neuroimage Clin. 2019. PMID: 30852397 Free PMC article.
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.
Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative. Shaw LM, et al. Among authors: potter w. Ann Neurol. 2009 Apr;65(4):403-13. doi: 10.1002/ana.21610. Ann Neurol. 2009. PMID: 19296504 Free PMC article.
Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.
Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dubé S, Mallinckrodt C, Bymaster FP, McKinzie DL, Felder CC. Shekhar A, et al. Among authors: potter wz. Am J Psychiatry. 2008 Aug;165(8):1033-9. doi: 10.1176/appi.ajp.2008.06091591. Epub 2008 Jul 1. Am J Psychiatry. 2008. PMID: 18593778 Clinical Trial.
A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia.
Krystal AD, Pizzagalli DA, Smoski M, Mathew SJ, Nurnberger J Jr, Lisanby SH, Iosifescu D, Murrough JW, Yang H, Weiner RD, Calabrese JR, Sanacora G, Hermes G, Keefe RSE, Song A, Goodman W, Szabo ST, Whitton AE, Gao K, Potter WZ. Krystal AD, et al. Among authors: potter wz. Nat Med. 2020 May;26(5):760-768. doi: 10.1038/s41591-020-0806-7. Epub 2020 Mar 30. Nat Med. 2020. PMID: 32231295 Clinical Trial.
Discovering translational biomarkers in neurodevelopmental disorders.
Sahin M, Jones SR, Sweeney JA, Berry-Kravis E, Connors BW, Ewen JB, Hartman AL, Levin AR, Potter WZ, Mamounas LA. Sahin M, et al. Among authors: potter wz. Nat Rev Drug Discov. 2018 Dec 20:10.1038/d41573-018-00010-7. doi: 10.1038/d41573-018-00010-7. Online ahead of print. Nat Rev Drug Discov. 2018. PMID: 30936503 Free PMC article.
Risk Assessment of Fluoride Intake from Tea in the Republic of Ireland and its Implications for Public Health and Water Fluoridation.
Waugh DT, Potter W, Limeback H, Godfrey M. Waugh DT, et al. Among authors: potter w. Int J Environ Res Public Health. 2016 Feb 26;13(3):259. doi: 10.3390/ijerph13030259. Int J Environ Res Public Health. 2016. PMID: 26927146 Free PMC article.
603 results
Jump to page
Feedback